- Home
- SAVA vs YI Comparison
SAVA vs YI Comparison
Compare SAVA & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAVA
- YI
- Stock Information
- Founded
- SAVA 1998
- YI 2010
- Country
- SAVA United States
- YI China
- Employees
- SAVA N/A
- YI N/A
- Industry
- SAVA Biotechnology: Pharmaceutical Preparations
- YI Retail-Drug Stores and Proprietary Stores
- Sector
- SAVA Health Care
- YI Consumer Staples
- Exchange
- SAVA Nasdaq
- YI Nasdaq
- Market Cap
- SAVA 70.5M
- YI 70.0M
- IPO Year
- SAVA N/A
- YI N/A
- Fundamental
- Price
- SAVA $2.35
- YI $7.32
- Analyst Decision
- SAVA Buy
- YI
- Analyst Count
- SAVA 2
- YI 0
- Target Price
- SAVA $54.50
- YI N/A
- AVG Volume (30 Days)
- SAVA 1.2M
- YI 9.2K
- Earning Date
- SAVA 08-07-2025
- YI 08-28-2025
- Dividend Yield
- SAVA N/A
- YI N/A
- EPS Growth
- SAVA N/A
- YI N/A
- EPS
- SAVA N/A
- YI N/A
- Revenue
- SAVA N/A
- YI $1,984,717,013.00
- Revenue This Year
- SAVA N/A
- YI N/A
- Revenue Next Year
- SAVA N/A
- YI N/A
- P/E Ratio
- SAVA N/A
- YI N/A
- Revenue Growth
- SAVA N/A
- YI N/A
- 52 Week Low
- SAVA $1.15
- YI $4.15
- 52 Week High
- SAVA $42.20
- YI $12.60
- Technical
- Relative Strength Index (RSI)
- SAVA 56.89
- YI 42.76
- Support Level
- SAVA $2.11
- YI $7.10
- Resistance Level
- SAVA $2.72
- YI $7.65
- Average True Range (ATR)
- SAVA 0.16
- YI 0.18
- MACD
- SAVA 0.04
- YI 0.01
- Stochastic Oscillator
- SAVA 52.56
- YI 28.27
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.
About YI 111 Inc.
111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.